Curative Biotechnology Inc (CUBT)

Curative Biotechnology, Inc. is a biopharmaceutical company that finds, in-licenses and develops drug candidates for rare diseases. Its pipeline includes a reformulation of Metformin for intermediate dry macular degeneration and geographic atrophy; IMT504, a new immunotherapy for late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody that carries a cytotoxic drug to the tumor to stop its growth and spread.

It has a licensing and co-development deal with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 for late-stage rabies and a COVID-19 vaccine. It also works with the University of Pennsylvania School of Veterinary Medicine on an eye formulation based on metformin. The company was founded in 1995 and is based in Palm Beach Gardens, Florida.